The statistical risk of diagnosing coincidental acquired hemophilia A following anti‐SARS‐CoV‐2 vaccination

We read with interest the case report by Radwi et al. of a 69 year-old man with acquired hemophilia A (AHA) following vaccination with the Pfizer-BioNTech SARS CoV-2 mRNA vaccine (1). The publication prompted us to perform a survey within the Working Party Haemostasis of the Swiss Society of Hematol...

Full description

Saved in:
Bibliographic Details
Published inJournal of Thrombosis and Haemostasis Vol. 19; no. 9; pp. 2360 - 2362
Main Authors Cittone, Micol G., Battegay, Raphael, Condoluci, Adalgisa, Terzi di Bergamo, Lodovico, Fernandes, Eliana, Galfetti, Elena, Noseda, Roberta, Leuppi‐Taegtmeyer, Anne, Drexler, Beatrice, Ceschi, Alessandro, Tsakiris, Dimitrios A., Berger, Christoph T., Favre, Genevieve, Martin, Thomas, Korte, Wolfgang, Graf, Lukas, Martinez, Maria, Gerber, Bernhard
Format Journal Article Web Resource
LanguageEnglish
Published England John Wiley & Sons, Inc 01.09.2021
Elsevier Limited
International Society on Thrombosis and Haemostasis. Published by Elsevier Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We read with interest the case report by Radwi et al. of a 69 year-old man with acquired hemophilia A (AHA) following vaccination with the Pfizer-BioNTech SARS CoV-2 mRNA vaccine (1). The publication prompted us to perform a survey within the Working Party Haemostasis of the Swiss Society of Hematology to detect similar cases in Switzerland. The survey led to the identification of three cases of AHA in Switzerland between December 23rd 2020 and April 30th 2021.
Bibliography:Final decision: David Lillicrap, 29 May 2021
Cittone and Battegay contributed equally to this article.
Gerber On behalf of the Working Party Haemostasis Switzerland
Manuscript handled by: David Lillicrap
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/jth.15421